Peptide Schedule
Eptifibatide (Integrilin)8 residuesHARGDWPCEach bubble = one amino acid. Size = residue mass. Color = chemical class.Eptifibatide (Integrilin) Dosage Calculator
Eptifibatide is a synthetic cyclic heptapeptide derived from the Lys-Gly-Asp (KGD) recognition sequence of barbourin, a disintegrin protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri).
180mcg · Single dose
Summary: Add 0mL BAC water to your 20mg vial. Draw to < 0.1 units on a U-100 syringe for a 180mcg dose. This vial will last 0 doses.
Cycle Planner
Eptifibatide (Integrilin) Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~2.5 hoursDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Eptifibatide (Integrilin) Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 180mcg | Single dose |
| Moderate | 180mcg | Single dose |
| Aggressive | 360mcg | Single dose |
Note: Eptifibatide (Integrilin) is an FDA-approved cyclic heptapeptide glycoprotein IIb/IIIa receptor antagonist used exclusively in the acute hospital setting for patients with acute coronary syndromes (ACS) and those undergoing percutaneous coronary intervention (PCI). It is supplied as a ready-to-use sterile solution for intravenous administration and does not require reconstitution with bacteriostatic water. Dosing is weight-based, typically 180 mcg/kg IV bolus followed by a continuous infusion of 2 mcg/kg/min. For PCI, a double-bolus regimen is standard, with a second 180 mcg/kg bolus administered 10 minutes after the first. The infusion may continue for up to 18-24 hours post-PCI or up to 72 hours in medically managed ACS. Eptifibatide must be used under close medical supervision with continuous hemodynamic monitoring and platelet count surveillance.
About Eptifibatide (Integrilin)
Eptifibatide is a synthetic cyclic heptapeptide derived from the Lys-Gly-Asp (KGD) recognition sequence of barbourin, a disintegrin protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). Marketed under the brand name Integrilin, eptifibatide received FDA approval in 1998 and remains a cornerstone antiplatelet agent used in interventional cardiology. It functions as a reversible, competitive antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, the final common pathway mediating platelet aggregation. The GP IIb/IIIa receptor is the most abundant integrin on the platelet surface, with approximately 80,000 copies per platelet. Upon platelet activation, this receptor undergoes a conformational change that enables high-affinity binding of fibrinogen and von Willebrand factor, effectively cross-linking adjacent platelets and forming a stable thrombus. Eptifibatide blocks this process by occupying the ligand-binding site on activated GP IIb/IIIa, preventing fibrinogen bridging between platelets. Clinically, eptifibatide is indicated for the management of patients with acute coronary syndromes (unstable angina and non-ST-elevation myocardial infarction) who are being managed medically or with percutaneous coronary intervention (PCI). Two landmark trials established its efficacy: the PURSUIT trial demonstrated a significant reduction in the composite endpoint of death or myocardial infarction at 30 days in ACS patients, while the ESPRIT trial showed substantial benefit in patients undergoing elective coronary stenting, with a 37% relative risk reduction in death or MI at six months. Eptifibatide is administered exclusively by the intravenous route in monitored hospital settings. Its pharmacokinetic profile is characterized by linear, dose-proportional kinetics, rapid onset of action, a short elimination half-life of approximately 2.5 hours, and rapid reversibility of platelet inhibition within 4-8 hours of discontinuation. About 50% of the drug is cleared renally, requiring dose adjustment in patients with moderate renal impairment.